Insider Steven Love Buys 20,000 Shares of OmniAb, Inc.
On June 17, 2026, Steven Love purchased 20,000 shares of OmniAb, Inc.
Key Points
- Steven Love acquired 20,000 shares of OmniAb, Inc. on June 17, 2026, with the stock trading at $2.34.
- OmniAb, Inc. has a market cap of $339.2 million and trades on the NasdaqGM with a 52-week range of $1.30 to $2.79.
- Peers like BlackRock and Geode Capital have also adjusted their positions in OmniAb, Inc., with BlackRock adding 41,900 shares.
On June 17, 2026, Steven Love made an insider purchase of 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). This transaction did not have a reported value or price, but it demonstrates Love's interest in increasing his stake in the company.
Other Institutional Activity in OmniAb, Inc.
Several institutional investors have also been active in OmniAb, Inc. BlackRock, Inc. increased its holdings by 41,900 shares, bringing its total to 8,106,881 shares valued at about $12.7 million. Geode Capital Management, LLC boosted its position by 202,887 shares, ending with 2,925,579 shares worth approximately $4.6 million. Meanwhile, Cadian Capital Management, LP reduced its stake by 277,825 shares, leaving it with 4,157,129 shares valued at $6.5 million.
OmniAb, Inc. Stock Snapshot
Shares of OmniAb, Inc. traded at $2.34 recently. The company, with a market capitalization of $339.2 million, operates in the biotechnology sector. It has a beta of 1.146, indicating moderate volatility. The stock's 52-week range is between $1.30 and $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80. OmniAb has a strong current ratio of 4.80 and a quick ratio of 4.55, though it carries a debt-to-equity ratio of 7.49.
Recent Earnings
OmniAb, Inc. reported revenue of $28.9 million, reflecting a modest growth rate of 2.47%. However, the company is not yet profitable, with a negative EPS of $0.46 and a net margin of -187.59%. Return on equity stands at -20.25%. The next earnings report is anticipated on August 6, 2026.
Insider Buying and Selling at OmniAb, Inc.
Alongside Steven Love's purchase, several other insiders made transactions on June 17, 2026. Jennifer Cochran acquired 40,000 shares and sold 20,000 shares. Carolyn Bertozzi bought 40,000 shares and sold 20,000 shares, while John Higgins purchased 20,000 shares. None of these transactions were planned sales.
Analysts Set New Price Targets
Analyst firms have shown interest in OmniAb, Inc. with RBC Capital maintaining a 'buy' rating and setting a price target of $3.0 as of August 7, 2025. Benchmark reiterated a 'buy' rating with a target of $6.0 on May 12, 2025. The consensus target mean price stands at $7.33, with six analysts providing opinions.
About OmniAb, Inc.
OmniAb, Inc., based in Emeryville, California, is a biotechnology company that licenses technology for drug discovery. Its platform helps pharmaceutical and biotech companies develop therapeutic antibodies. The company utilizes genetically modified animals and AI tools to create optimized antibody candidates. OmniAb was founded in 2012 and is led by CEO Matthew W. Foehr.
Bottom Line
Insider purchases like Steven Love's can be a signal of confidence in OmniAb, Inc. Investors often track such transactions to gauge insider sentiment. The company's recent institutional activity and analyst ratings suggest varied interest. As always, it's important to remember that insider transactions are disclosed after the fact, providing a historical view of ownership changes.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.